瑞格非尼-话题@MedSci

#瑞格非尼#

5篇内容 | 585人围观

关注话题

话题活跃用户

#插入话题

插入图片

最新最热

[GetTopicListResponse(id=1775964, encodeId=4d411e7596445, content=<a href='/topic/show?id=5ea868e3360' target=_blank style='color:#2F92EE;'>#瑞格非尼#</a>, objectTitle=基石药业宣布与拜耳合作，评估其PD-L1单抗CS1001与瑞格非尼的联合抗胃癌疗效, objectType=article, longId=168072, objectId=0b361680e285, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=0b361680e285, replyNumber=0, likeNumber=30, createdTime=2020-01-11, rootId=0, userName=hongbochen, userId=d29038846779, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=0b361680e285, moduleTitle=基石药业宣布与拜耳合作，评估其PD-L1单抗CS1001与瑞格非尼的联合抗胃癌疗效, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=0b361680e285)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1775966, encodeId=0e0d1e7596606, content=<a href='/topic/show?id=5ea868e3360' target=_blank style='color:#2F92EE;'>#瑞格非尼#</a>, objectTitle=2019年ESMO世界胃肠癌大会：灵活剂量的瑞格非尼可有效缓解其在转移性结直肠癌患者中的副作用, objectType=article, longId=175018, objectId=a1a91e501898, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=a1a91e501898, replyNumber=0, likeNumber=33, createdTime=2019-10-26, rootId=0, userName=hongbochen, userId=d29038846779, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=a1a91e501898, moduleTitle=2019年ESMO世界胃肠癌大会：灵活剂量的瑞格非尼可有效缓解其在转移性结直肠癌患者中的副作用, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=a1a91e501898)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1775965, encodeId=2e191e75965b9, content=<a href='/topic/show?id=5ea868e3360' target=_blank style='color:#2F92EE;'>#瑞格非尼#</a>, objectTitle=Lancet Oncol：改良瑞格非尼剂量方案以降低晚期结肠癌不良事件风险, objectType=article, longId=174704, objectId=20e71e47040d, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=20e71e47040d, replyNumber=0, likeNumber=28, createdTime=2019-08-23, rootId=0, userName=hongbochen, userId=d29038846779, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=20e71e47040d, moduleTitle=Lancet Oncol：改良瑞格非尼剂量方案以降低晚期结肠癌不良事件风险, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=20e71e47040d)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1775963, encodeId=7fce1e759631f, content=<a href='/topic/show?id=5ea868e3360' target=_blank style='color:#2F92EE;'>#瑞格非尼#</a>, objectTitle=瑞格非尼获欧盟批准用于胃肠道间质瘤治疗, objectType=article, longId=38600, objectId=b8f43860005, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=b8f43860005, replyNumber=0, likeNumber=28, createdTime=2015-03-06, rootId=0, userName=hongbochen, userId=d29038846779, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=b8f43860005, moduleTitle=瑞格非尼获欧盟批准用于胃肠道间质瘤治疗, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=b8f43860005)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1775962, encodeId=582d1e7596200, content=<a href='/topic/show?id=5ea868e3360' target=_blank style='color:#2F92EE;'>#瑞格非尼#</a>, objectTitle=FDA批准瑞格非尼治疗晚期胃肠间质肿瘤, objectType=article, longId=15386, objectId=9fd415386bc, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=9fd415386bc, replyNumber=0, likeNumber=36, createdTime=2013-05-15, rootId=0, userName=hongbochen, userId=d29038846779, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=9fd415386bc, moduleTitle=FDA批准瑞格非尼治疗晚期胃肠间质肿瘤, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=9fd415386bc)], followStatus=false, userIsMember=false, type=1, lengthMark=0)] 梅斯话题小助手

2020-05-29

hongbochen (审核中...)

前往app查看评论内容

#瑞格非尼#

基石药业宣布与拜耳合作，评估其PD-L1单抗CS1001与瑞格非尼的联合抗胃癌疗效

2020-01-11

hongbochen (审核中...)

前往app查看评论内容

#瑞格非尼#

2019年ESMO世界胃肠癌大会：灵活剂量的瑞格非尼可有效缓解其在转移性结直肠癌患者中的副作用

2019-10-26

hongbochen (审核中...)

前往app查看评论内容

#瑞格非尼#

Lancet Oncol：改良瑞格非尼剂量方案以降低晚期结肠癌不良事件风险

2019-08-23

hongbochen (审核中...)

前往app查看评论内容

#瑞格非尼#

瑞格非尼获欧盟批准用于胃肠道间质瘤治疗

2015-03-06

hongbochen (审核中...)

前往app查看评论内容

#瑞格非尼#

FDA批准瑞格非尼治疗晚期胃肠间质肿瘤

2013-05-15

科室
- - 订阅+
  - 更多科室
工具
服务